Source: Atherosclerosis. Unidade: IQ
Subjects: LIPOPROTEÍNAS, DIABETES MELLITUS
ABNT
BONILHA, Isabella et al. LDL subspecies and lipidome change by evolocumab add-on therapy to empagliflozin in patients with type 2 diabetes: a prespecified secondary analysis of a randomized clinical trial. Atherosclerosis, v. 415, p. 1-10 art. 120686, 2026Tradução . . Disponível em: https://dx.doi.org/10.1016/j.atherosclerosis.2026.120686. Acesso em: 25 abr. 2026.APA
Bonilha, I., Yoshinaga, M. Y., Chaves Filho, A. de B., Gomes, É. I. L., Santos, R. S., Breder, I., et al. (2026). LDL subspecies and lipidome change by evolocumab add-on therapy to empagliflozin in patients with type 2 diabetes: a prespecified secondary analysis of a randomized clinical trial. Atherosclerosis, 415, 1-10 art. 120686. doi:10.1016/j.atherosclerosis.2026.120686NLM
Bonilha I, Yoshinaga MY, Chaves Filho A de B, Gomes ÉIL, Santos RS, Breder I, Breder J, Miyamoto S, Nadruz W, Kontush A, Sposito AC. LDL subspecies and lipidome change by evolocumab add-on therapy to empagliflozin in patients with type 2 diabetes: a prespecified secondary analysis of a randomized clinical trial [Internet]. Atherosclerosis. 2026 ; 415 1-10 art. 120686.[citado 2026 abr. 25 ] Available from: https://dx.doi.org/10.1016/j.atherosclerosis.2026.120686Vancouver
Bonilha I, Yoshinaga MY, Chaves Filho A de B, Gomes ÉIL, Santos RS, Breder I, Breder J, Miyamoto S, Nadruz W, Kontush A, Sposito AC. LDL subspecies and lipidome change by evolocumab add-on therapy to empagliflozin in patients with type 2 diabetes: a prespecified secondary analysis of a randomized clinical trial [Internet]. Atherosclerosis. 2026 ; 415 1-10 art. 120686.[citado 2026 abr. 25 ] Available from: https://dx.doi.org/10.1016/j.atherosclerosis.2026.120686
